Core Insights - In 2025, Chinese biopharmaceutical companies achieved a record high in out-licensing deals, surpassing $137.7 billion, nearly a tenfold increase from 2021, with 186 transactions [3] Group 1: Market Trends - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, signed significant agreements with Chinese firms last year [4] - The total value of these licensing deals is expected to double in the next 18 to 24 months, as global companies focus on finding next-generation innovative drug pipelines in China [4] - Nearly 40 out-licensing transactions have occurred this year, with average deal sizes significantly higher than last year [4] Group 2: Notable Transactions - On February 8, Innovent Biologics entered a strategic partnership with Eli Lilly, securing a total payment of $8.85 billion, including an upfront payment of $350 million and milestone payments of $8.5 billion [5] - Madrigal Pharmaceuticals announced a licensing agreement with Suzhou Ribo Biopharma for an experimental liver disease project, with a potential deal size of $4.4 billion [5] - AstraZeneca reached a collaboration agreement with China’s CSPC Pharmaceutical Group, potentially valued at $18.5 billion, to develop a next-generation GLP-1 weight loss therapy [5] Group 3: Industry Analysis - Macquarie Capital predicts that oncology drugs will continue to attract global pharmaceutical interest, highlighting China's strong capabilities in chemical drug development despite a gap in biological fields compared to the U.S. [6] - Multinational companies view China as a crucial part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [6] - Vision Lifesciences' report indicates that China leads globally in specific molecular types, with Chinese companies accounting for nearly 90% of global out-licensing transactions for antibody-drug conjugates (ADCs) [6]

Group 1 - In 2025, Chinese biopharmaceutical companies achieved a record high in outbound licensing deals, surpassing $137.7 billion, nearly a tenfold increase from 2021, with 186 transactions [1] - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, signed significant agreements with Chinese firms last year [1] - Tom Barsha from Bank of America Securities predicts that the total value of these licensing deals could double again in the next 18 to 24 months, as global companies focus on finding next-generation innovative drug pipelines in China [1] Group 2 - AstraZeneca announced a collaboration with China’s CSPC Pharmaceutical Group, potentially worth up to $18.5 billion, to develop a next-generation GLP-1 class weight loss therapy [2] - The average deal size for outbound licensing by Chinese pharmaceutical companies has reached $1.3 billion this year, a 76% increase from 2025 and six times the average level of 2021 [2] - Macquarie Capital analysts noted that many multinational companies view China as a crucial part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [2]